Chinese expert consensus on perioperative management of renal tumor cryoablation (2022 edition) / 中华内科杂志
Chinese Journal of Internal Medicine
; (12): 363-368, 2023.
Article
en Zh
| WPRIM
| ID: wpr-985934
Biblioteca responsable:
WPRO
ABSTRACT
In recent years, the incidence of renal cancer has been increasing continuously. Surgical resection is the "gold standard" for the treatment of small renal cancer. However, local ablation therapy of renal cancer is undoubtedly the best choice for patients with short life expectancy, other complications, and impaired renal function who are not suitable for surgery. In recent years, with the development of ablation techniques and long-term follow-up, local ablation has shown good therapeutic effects. As many domestic hospitals are performing or planning to perform renal tumor cryoablation to improve the clinical cure rate and surgical safety of renal tumor cryoablation, it is necessary to standardize the surgical indications, contraindications, perioperative management, efficacy evaluation, and other common problems. Currently, there is no expert consensus regarding perioperative renal tumor cryoablation in China. To standardize the perioperative management of renal tumor cryoablation and related technical operations in clinical practice, and improve the effectiveness and safety of cryoablation, the expert committee of Tumor Interventional and Minimally Invasive Diagnosis and Treatment Continuing Education Base of the Chinese Anti-Cancer Association convened experts in related fields to discuss and formulate this consensus, which is hereby published, for clinical reference and application.
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Carcinoma de Células Renales
/
China
/
Resultado del Tratamiento
/
Criocirugía
/
Consenso
/
Neoplasias Renales
Límite:
Humans
País/Región como asunto:
Asia
Idioma:
Zh
Revista:
Chinese Journal of Internal Medicine
Año:
2023
Tipo del documento:
Article